Is Ozempic for Diabetes or Weight Loss?

Last reviewed: June 19, 2026

Last updated: June 19, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active ingredient in Ozempic, was first approved by the FDA in 2017 for type 2 diabetes management. Within five years, the medication gained widespread attention for its powerful weight loss effects, with clinical data showing participants lost up to 15% of body weight over 68 weeks. The truth is that Ozempic addresses both conditions simultaneously through a single biological mechanism.

How Semaglutide Works for Both Diabetes and Weight Loss

Semaglutide mimics glucagon-like peptide-1 (GLP-1), a natural hormone that regulates blood sugar and appetite. When injected weekly, it activates GLP-1 receptors in the pancreas, intestines, and brain. In the pancreas, it stimulates insulin release when blood glucose rises. In the digestive tract, it slows stomach emptying, making you feel fuller longer. In the brain, it reduces hunger signals and increases satiety—the same pathways that control blood sugar also control appetite.

For people with type 2 diabetes, the blood sugar regulation effect is primary. For people managing weight without diabetes, the appetite-suppressing effect is primary. Both outcomes result from the same medication acting on the same receptor network. This explains why semaglutide carries FDA approval for both diabetes management and chronic weight management under different brand names—Ozempic for diabetes and Wegovy for weight loss.

Ozempic for Type 2 Diabetes: Clinical Evidence

In the SUSTAIN clinical trial series, patients taking semaglutide for type 2 diabetes achieved an average HbA1c reduction of 1.5% compared to placebo, bringing many participants closer to normal glucose levels. HbA1c measures average blood sugar over three months; a 1.5% drop is clinically significant and often reduces the need for additional diabetes medications. Beyond glucose control, trial participants also lost an average of 4–6 kg, even though weight loss was not the stated goal of diabetes management.

Cardiovascular outcomes matter for diabetic patients. The SUSTAIN-6 trial demonstrated that semaglutide reduced the risk of major adverse cardiac events by 26% in people with established heart disease or high cardiovascular risk. This benefit extends beyond weight loss alone—semaglutide appears to protect blood vessels and reduce inflammation independently. For diabetes patients, these dual benefits make semaglutide a foundational therapy, not just a glucose-lowering agent.

Semaglutide for Weight Loss: What the Data Shows

The STEP clinical trial program tested semaglutide specifically for chronic weight management in people without diabetes. Participants receiving a 2.4 mg weekly injection lost an average of 15.3% of body weight over 68 weeks, compared to 2.6% in the placebo group. Approximately 86% of participants lost at least 5% of baseline weight—a threshold associated with improvements in blood pressure, cholesterol, and joint stress. These results represent the largest weight loss achieved by a single medication in modern obesity medicine.

Weight loss from semaglutide is sustained only while taking the medication. When people stop the injection, weight gradually returns over 6–12 months. This underscores that semaglutide is not a permanent cure but rather a tool for managing a chronic condition. Like blood pressure medication or diabetes treatment, it works only while in use—which is why PlexusDx designs flexible, month-to-month treatment plans without long-term commitments.

Compounded Semaglutide from PlexusDx vs. Brand-Name Ozempic

PlexusDx offers compounded semaglutide injection prepared by licensed 503A compounding pharmacies, providing the same active pharmaceutical ingredient as Ozempic at a lower cost. Compounded medications are produced under strict pharmaceutical standards and must meet USP (United States Pharmacopeia) specifications for purity, potency, and sterility. The key difference is that compounded semaglutide is not mass-manufactured by a pharmaceutical corporation; instead, it is prepared in smaller batches by licensed pharmacists. No insurance is required, and treatment is $189/mo month-to-month, or from $149/mo on the 6-month plan, with pricing that remains flat regardless of dose level—your dose may need to go up, but your price won't.

PlexusDx serves all 50 states and makes treatment HSA/FSA eligible, removing barriers that prevent many people from accessing semaglutide. Patients may also add the Precision Peptide Genetic Test ($298) to understand how their individual genetic variants in the GLP-1 receptor, GIPR, FTO, and MC4R genes influence their response to treatment. This personalization helps describe the pathway-level variants involved.

Is Semaglutide Right for You: Diabetes, Weight Loss, or Both?

Semaglutide is indicated for type 2 diabetes in adults and chronic weight management in people with a body mass index (BMI) of 30 kg/m² or higher, or BMI of 27 kg/m² or higher with at least one weight-related condition such as hypertension, dyslipidemia, or sleep apnea. Many people qualify for both uses simultaneously if they have type 2 diabetes and elevated BMI. A healthcare provider will evaluate your medical history, current medications, and weight-related health conditions to determine the appropriate starting dose and treatment plan.

Common side effects include nausea, vomiting, diarrhea, and constipation, particularly during the first 4–8 weeks as the body adjusts. These effects typically decrease over time. Rare but serious risks include pancreatitis, gallbladder disease, and thyroid concerns—individuals with a personal or family history of medullary thyroid carcinoma should not use semaglutide. PlexusDx works with patients to monitor tolerability and adjust dosing as needed, ensuring the medication supports long-term health rather than creating unmanageable side effects.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic only for diabetes, or can it be used for weight loss?

Ozempic (semaglutide) is FDA-approved for type 2 diabetes, while Wegovy is the brand name for the same medication approved for chronic weight management. The active ingredient works identically in both cases, so semaglutide addresses both blood sugar control and appetite suppression. PlexusDx offers compounded semaglutide at $189/mo month-to-month, or from $149/mo on the 6-month plan for either indication, with dosing guided by your provider and health goals.

How much weight can I expect to lose with semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to Ozempic or any specific medication. It analyzes pathway-level variants (FTO (rs9939609)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Why is PlexusDx compounded semaglutide cheaper than Ozempic?

Compounded semaglutide is prepared in licensed 503A pharmacies rather than mass-manufactured by a large pharmaceutical corporation, eliminating marketing and distribution overhead. PlexusDx passes those savings directly to patients—treatment is $189/mo month-to-monthnth with flat pricing regardless of dose, no insurance required, and HSA/FSA eligibility. All medications meet USP standards for purity and potency, ensuring safety and efficacy.

What are the main side effects of semaglutide, and how long do they last?

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, typically occurring during the first 4–8 weeks as your body adapts. These effects usually decrease with time as your system stabilizes. Serious but rare complications include pancreatitis and gallbladder issues. PlexusDx monitors tolerability throughout treatment and adjusts your plan if side effects become problematic, ensuring semaglutide enhances rather than detracts from your quality of life.

Can the Precision Peptide Genetic Test tell me if semaglutide will work for me?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.